Protagenic Historical Balance Sheet

PTIX Stock

USD 0.52 0.03 5.45%

Trend analysis of Protagenic Therapeutics balance sheet accounts such as Total Stockholder Equity of 6.1 M, Property Plant And Equipment Net of 117.2 K, Cash of 2 M or Non Current Assets Total of 117.2 K provides information on Protagenic Therapeutics' total assets, liabilities, and equity, which is the actual value of Protagenic Therapeutics to its prevalent stockholders. By breaking down trends over time using Protagenic Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Protagenic Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Protagenic Therapeutics is a good buy for the upcoming year.

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Protagenic Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy Protagenic Stock please use our How to Invest in Protagenic Therapeutics guide.

About Protagenic Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Protagenic Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Protagenic Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Protagenic Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Protagenic currently owns. An asset can also be divided into two categories, current and non-current.

Protagenic Therapeutics Balance Sheet Chart

At this time, Protagenic Therapeutics' Total Stockholder Equity is fairly stable compared to the past year. Cash is likely to rise to about 2 M in 2024, whereas Total Assets are likely to drop slightly above 4.1 M in 2024.

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities Retained Earnings Non Currrent Assets Other

Add Fundamental

Total Assets

Total assets refers to the total amount of Protagenic Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Protagenic Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Protagenic Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Protagenic Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Retained Earnings

The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.

Non Currrent Assets Other

Assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents.

Most accounts from Protagenic Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Protagenic Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Protagenic Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy Protagenic Stock please use our How to Invest in Protagenic Therapeutics guide.At this time, Protagenic Therapeutics' Total Stockholder Equity is fairly stable compared to the past year. Cash is likely to rise to about 2 M in 2024, whereas Total Assets are likely to drop slightly above 4.1 M in 2024.

	2021	2022	2023	2024 (projected)
Short and Long Term Debt Total	318.4K	344.2K	309.8K	294.3K
Total Assets	11.1M	8.0M	4.3M	4.1M

Short Long Term Debt Total Total Assets

Protagenic Therapeutics balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Accounts Payable	Short Term Investments	Current Deferred Revenue	Other Assets	Net Tangible Assets
Total Assets		-0.34	0.1	-0.09	0.65	-0.18	-0.33	-0.03	0.22	-0.19	-0.19	1.0	-0.24	0.58	-0.25	0.68	-0.07	-0.11	0.97	-0.24	-0.24	-0.12	0.93	-0.2	-0.27	0.83
Short Long Term Debt Total	-0.34		-0.09	0.54	-0.63	0.36	0.76	-0.48	-0.24	0.37	0.37	-0.31	0.83	-0.26	0.87	-0.23	0.79	0.57	-0.35	0.95	0.83	0.57	-0.22	0.38	-0.28	-0.38
Other Current Liab	0.1	-0.09		-0.27	0.26	0.64	-0.21	0.25	0.16	0.64	0.64	0.12	-0.44	0.7	-0.4	-0.04	-0.39	-0.27	0.09	-0.05	-0.44	-0.31	0.23	0.64	-0.44	0.07
Total Current Liabilities	-0.09	0.54	-0.27		-0.81	-0.1	0.38	-0.98	0.03	-0.1	-0.1	-0.11	0.66	-0.29	0.66	-0.22	0.65	1.0	-0.1	0.56	0.66	1.0	-0.14	-0.09	-0.14	-0.15
Total Stockholder Equity	0.65	-0.63	0.26	-0.81		-0.03	-0.52	0.72	0.16	-0.04	-0.04	0.66	-0.64	0.59	-0.65	0.53	-0.53	-0.82	0.67	-0.57	-0.64	-0.82	0.63	-0.05	-0.06	0.65
Property Plant And Equipment Net	-0.18	0.36	0.64	-0.1	-0.03		0.29	0.13	-0.18	1.0	1.0	-0.15	-0.11	0.35	-0.05	-0.11	-0.14	-0.09	-0.18	0.4	-0.11	-0.08	0.1	1.0	-0.12	-0.13
Net Debt	-0.33	0.76	-0.21	0.38	-0.52	0.29		-0.31	-0.79	0.31	0.32	-0.31	0.61	-0.31	0.65	-0.09	0.53	0.42	-0.37	0.71	0.61	0.42	-0.07	0.32	0.03	-0.45
Retained Earnings	-0.03	-0.48	0.25	-0.98	0.72	0.13	-0.31		-0.1	0.13	0.14	-0.01	-0.61	0.15	-0.61	0.16	-0.65	-0.98	-0.04	-0.51	-0.61	-0.97	0.04	0.13	0.2	-0.01
Cash	0.22	-0.24	0.16	0.03	0.16	-0.18	-0.79	-0.1		-0.19	-0.21	0.21	-0.15	0.22	-0.18	-0.05	-0.06	0.01	0.3	-0.22	-0.15	0.0	-0.07	-0.21	-0.28	0.37
Non Current Assets Total	-0.19	0.37	0.64	-0.1	-0.04	1.0	0.31	0.13	-0.19		1.0	-0.16	-0.1	0.33	-0.04	-0.11	-0.14	-0.09	-0.19	0.4	-0.1	-0.07	0.09	1.0	-0.11	-0.16
Non Currrent Assets Other	-0.19	0.37	0.64	-0.1	-0.04	1.0	0.32	0.14	-0.21	1.0		-0.15	-0.1	0.32	-0.04	-0.1	-0.14	-0.09	-0.19	0.4	-0.1	-0.07	0.1	1.0	-0.11	-0.18
Cash And Short Term Investments	1.0	-0.31	0.12	-0.11	0.66	-0.15	-0.31	-0.01	0.21	-0.16	-0.15		-0.22	0.59	-0.22	0.66	-0.04	-0.13	0.97	-0.2	-0.22	-0.14	0.94	-0.16	-0.3	0.83
Common Stock Total Equity	-0.24	0.83	-0.44	0.66	-0.64	-0.11	0.61	-0.61	-0.15	-0.1	-0.1	-0.22		-0.48	1.0	-0.25	0.97	0.67	-0.25	0.86	1.0	0.68	-0.24	-0.1	-0.16	-0.26
Common Stock Shares Outstanding	0.58	-0.26	0.7	-0.29	0.59	0.35	-0.31	0.15	0.22	0.33	0.32	0.59	-0.48		-0.46	0.27	-0.31	-0.3	0.63	-0.2	-0.49	-0.33	0.64	0.31	-0.48	0.7
Non Current Liabilities Total	-0.25	0.87	-0.4	0.66	-0.65	-0.05	0.65	-0.61	-0.18	-0.04	-0.04	-0.22	1.0	-0.46		-0.25	0.97	0.67	-0.26	0.89	1.0	0.68	-0.23	-0.03	-0.17	-0.28
Other Current Assets	0.68	-0.23	-0.04	-0.22	0.53	-0.11	-0.09	0.16	-0.05	-0.11	-0.1	0.66	-0.25	0.27	-0.25		-0.17	-0.21	0.64	-0.26	-0.25	-0.22	0.67	-0.11	-0.07	0.41
Other Stockholder Equity	-0.07	0.79	-0.39	0.65	-0.53	-0.14	0.53	-0.65	-0.06	-0.14	-0.14	-0.04	0.97	-0.31	0.97	-0.17		0.66	-0.06	0.84	0.97	0.67	-0.09	-0.14	-0.26	-0.06
Total Liab	-0.11	0.57	-0.27	1.0	-0.82	-0.09	0.42	-0.98	0.01	-0.09	-0.09	-0.13	0.67	-0.3	0.67	-0.21	0.66		-0.12	0.57	0.67	0.99	-0.15	-0.08	-0.15	-0.18
Total Current Assets	0.97	-0.35	0.09	-0.1	0.67	-0.18	-0.37	-0.04	0.3	-0.19	-0.19	0.97	-0.25	0.63	-0.26	0.64	-0.06	-0.12		-0.25	-0.25	-0.13	0.89	-0.2	-0.28	0.89
Short Term Debt	-0.24	0.95	-0.05	0.56	-0.57	0.4	0.71	-0.51	-0.22	0.4	0.4	-0.2	0.86	-0.2	0.89	-0.26	0.84	0.57	-0.25		0.86	0.59	-0.1	0.41	-0.25	-0.24
Common Stock	-0.24	0.83	-0.44	0.66	-0.64	-0.11	0.61	-0.61	-0.15	-0.1	-0.1	-0.22	1.0	-0.49	1.0	-0.25	0.97	0.67	-0.25	0.86		0.68	-0.24	-0.1	-0.16	-0.27
Accounts Payable	-0.12	0.57	-0.31	1.0	-0.82	-0.08	0.42	-0.97	0.0	-0.07	-0.07	-0.14	0.68	-0.33	0.68	-0.22	0.67	0.99	-0.13	0.59	0.68		-0.16	-0.07	-0.1	-0.18
Short Term Investments	0.93	-0.22	0.23	-0.14	0.63	0.1	-0.07	0.04	-0.07	0.09	0.1	0.94	-0.24	0.64	-0.23	0.67	-0.09	-0.15	0.89	-0.1	-0.24	-0.16		0.09	-0.24	0.74
Current Deferred Revenue	-0.2	0.38	0.64	-0.09	-0.05	1.0	0.32	0.13	-0.21	1.0	1.0	-0.16	-0.1	0.31	-0.03	-0.11	-0.14	-0.08	-0.2	0.41	-0.1	-0.07	0.09		-0.11	-0.18
Other Assets	-0.27	-0.28	-0.44	-0.14	-0.06	-0.12	0.03	0.2	-0.28	-0.11	-0.11	-0.3	-0.16	-0.48	-0.17	-0.07	-0.26	-0.15	-0.28	-0.25	-0.16	-0.1	-0.24	-0.11		-0.25
Net Tangible Assets	0.83	-0.38	0.07	-0.15	0.65	-0.13	-0.45	-0.01	0.37	-0.16	-0.18	0.83	-0.26	0.7	-0.28	0.41	-0.06	-0.18	0.89	-0.24	-0.27	-0.18	0.74	-0.18	-0.25

Click cells to compare fundamentals

Protagenic Therapeutics Account Relationship Matchups

Protagenic Therapeutics balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	842.3K	879.2K	11.1M	8.0M	4.3M	4.1M
Other Current Liab	1.2M	513.3K	520.6K	620.1K	541.5K	514.4K
Total Current Liabilities	1.2M	655.2K	799.5K	1.1M	655.3K	622.5K
Total Stockholder Equity	(634.4K)	(1.1M)	9.9M	6.9M	3.7M	6.1M
Property Plant And Equipment Net	611.0	296.0	0.0	1.8K	123.3K	117.2K
Net Debt	(519.3K)	702.7K	(222.7K)	129.0K	(1.3M)	(1.4M)
Retained Earnings	(15.2M)	(17.7M)	(22.2M)	(25.8M)	(30.8M)	(32.3M)
Cash	798.6K	671.1K	541.2K	215.2K	1.3M	2.0M
Non Current Assets Total	611.0	296.0	0.0	1.8K	123.3K	117.2K
Non Currrent Assets Other	1.0K	611.0	296.0	1.8K	(1.0)	(0.95)
Cash And Short Term Investments	798.6K	671.1K	10.4M	8.0M	4.1M	4.0M
Liabilities And Stockholders Equity	842.3K	879.2K	11.1M	8.0M	4.3M	4.1M
Non Current Liabilities Total	161.0	52.4K	279.4K	1.4M	318.4K	1.0M
Other Current Assets	43.4K	208.2K	688.7K	56.9K	144.0K	136.8K
Other Stockholder Equity	14.7M	16.7M	32.4M	33.4M	34.6M	42.6M
Total Liab	1.5M	2.0M	1.1M	1.1M	655.3K	622.5K
Total Current Assets	842.0K	879.2K	11.1M	8.0M	4.2M	7.2M
Accumulated Other Comprehensive Income	(172.4K)	(171.6K)	(248.3K)	(676.9K)	(113.5K)	(119.2K)
Accounts Payable	36.2K	141.9K	279.0K	155.5K	113.8K	108.1K
Net Tangible Assets	(210.9K)	(634.4K)	(1.1M)	9.9M	11.4M	12.0M
Net Invested Capital	(355.0K)	224.1K	10.3M	7.3M	3.7M	3.5M
Net Working Capital	(355.3K)	224.1K	10.3M	6.9M	3.5M	3.4M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for Protagenic Stock Analysis

When running Protagenic Therapeutics' price analysis, check to measure Protagenic Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagenic Therapeutics is operating at the current time. Most of Protagenic Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagenic Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagenic Therapeutics' price. Additionally, you may evaluate how the addition of Protagenic Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Protagenic Historical Balance Sheet

About Protagenic Balance Sheet Analysis

Protagenic Therapeutics Balance Sheet Chart

Total Assets

Total Current Liabilities

Retained Earnings

Non Currrent Assets Other

Protagenic Therapeutics balance sheet Correlations

Protagenic Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Protagenic Therapeutics balance sheet Accounts

Also Currently Popular

Additional Tools for Protagenic Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Liab	+ 1.0	Total Current Liabilities
Accounts Payable	+ 1.0	Total Current Liabilities
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Non Currrent Assets Other	+ 1.0	Property Plant And Equipment Net
Current Deferred Revenue	+ 1.0	Property Plant And Equipment Net

Total Liab	- 0.98	Retained Earnings
Retained Earnings	- 0.98	Total Current Liabilities
Accounts Payable	- 0.97	Retained Earnings
Accounts Payable	- 0.82	Total Stockholder Equity
Total Liab	- 0.82	Total Stockholder Equity
Total Stockholder Equity	- 0.81	Total Current Liabilities